Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) Stock Overview
Explore Moleculin Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
MBRX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Moleculin Biotech, Inc. (MBRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.28.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.13 and a market capitalization of 4.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Mr. Walter V. Klemp
17
5300 Memorial Drive, Houston, TX
2016